Aldeyra Therapeutics Stock News

Shares of Aldeyra Therapeutics Inc. ALDX, -66.43% plummeted 61.9% toward a 3 1/2-year low in very active morning trading Monday, enough to pace the Nasdaq's decliners, after the Massachusetts-based bi

Shares of Aldeyra Therapeutics (NASDAQ:ALDX) have lost two-thirds of their value Monday after the company warned the US Food and Drug Administration may not approve its new drug application.  Minutes

Aldeyra is a late-stage company developing therapies for immune-mediated diseases, with a focus on dry eye disease and allergic conjunctivitis. Their lead asset, reproxalap, is under NDA review for dr

Aldeyra Therapeutics reported $165 million in cash and cash equivalents as of March 31, 2023, with a net loss of $15.6 million for Q1 2023. The company's drug, reproxalap, is under FDA review for trea

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, June 29, 2023, at 8:00 a.m. (ET) to provi

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, June 27, 2023, at 8:00 a.m. (ET) to provid

Aldeyra (ALDX) soars on meeting primary and secondary endpoints in the late-stage study of reproxalap for patients with allergic conjunctivitis.

Aldeyra Therapeutics reported positive results from a Phase III study of Reproxalap, an eye drop drug for allergic conjunctivitis and dry eye disease that provides immediate relief to patients. The tr

Aldeyra Therapeutics Inc (NASDAQ:ALDX) is up 14.1% at $11.93 at last glance, after the biotech's allergy treatment in the form of liquid eye drops, reproxalap, met its goal in a late-stage study.

Aldeyra Therapeutics (NASDAQ:ALDX) announced on Thursday that its investigational new drug reproxalap ophthalmic solution for patients with allergic conjunctivitis has achieved statistical significanc

Aldeyra Therapeutics said on Thursday its experimental drug to treat an inflammatory eye disease met the main goal of reducing itching in a late-stage study.

Aldeyra Therapeutics Inc.'s stock ALDX, +0.63% jumped 11% premarket Thursday, after the biotech announced positive results from a late-stage trial of a treatment for allergic conjunctivitis. The Lexin

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, June 15, 2023, at 8:00 a.m. (ET) to provi

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated dise

They headlined 3 top-line results coming in Q2 2023. An all-important PDUFA Date is on tap in June.